Leman Biotech is a clinical-stage biotechnology company focused on developing next-generation cancer immunotherapies through metabolic reprogramming. Their proprietary META 10 platform aims to reverse T cell exhaustion, a key bottleneck in immunotherapy efficacy. The company leverages AI and metabolic reprogramming to create cell therapies with improved safety, efficacy, and accessibility.